Sepracor ends Xopenex copromotion with Abbott
Sepracor's copromotion deal with Abbott's Ross division for Xopenex (levalbuterol) will end on Dec. 31. Sepracor is moving its sales force in-house as it ramps up for the launch of its insomnia agent Estorra (eszopiclone). Sepracor will expand sales force to approximately 1,250 reps. Estorra has been "approvable" at the agency since Feb. 27 (1"The Pink Sheet" March 8, 2004, p. 34)...
You may also be interested in...
Sepracor will resubmit its NDA for the insomnia agent Estorra in one to three months after receiving an "approvable" letter Feb. 27
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.